INTRODUCTION
c-Met is a tyrosine kinase receptor for hepatocyte growth factor (HGF), overexpressed or aberrantly activated in a variety of cancers, including renal, ovarian, lung, colorectal, breast, gastric, cervical, stomach, pancreatic, esophageal, and melanoma (1, 2) . The overexpression of cMet from gene amplification or mutation in cancer results in aberrant activation of the c-Met axis, leading to proliferation, apoptosis inhibition, angiogenesis and invasion of cancer cells (3) .
c-Met overexpression is also associated with poor clinical prognosis, elevated metastasis incurrence, and increased drug resistance of cancer (4, 5) . Together, these characteristics suggest that c-Met is an active participant in cancer initiation and progression, thus the assessment of cMet expression in real time could potentially aid in the diagnosis and monitoring of responses to relevant therapies.
Numerous studies also suggest that c-Met is an attractive drug target in cancer therapy because blocking of c-Met can usually result in the inhibition of tumor growth and metastasis (2, 6) . Multiple clinical trials have adopted tyrosine kinase inhibitors and monoclonal antibodies (mAbs) against c-Met pathways as cancer therapeutic agents (7) (8) (9) . Diagnostic methods that can help to identify the suitable patient population for c-Met targeted therapy are fundamental to produce improved clinic outcome. The current patient selection standard is usually based on immunohistochemistry or fluorescent in situ hybridization (FISH) . Despite the fact that these methods can provide quantitative information about c-Met abundance, they are not applicable in two scenarios: reflecting c-Met expression fluctuation over time, and dealing with c-Met heterogeneity in different tumor sites. Positron emission tomography (PET) imaging can overcome these limitations due to its high sensitivity to detect molecular events in a real time manner. Several radiolabeled antibodies against c-Met were already used for in vivo tumor by on (10) . Other choices such as DN30 and onartuzumab were also labeled with 89 Zr for imaging c-Met expression in vivo with good tumor uptake (11, 12) . However, the prolonged circulation time and slow clearance can lead to low tumor-to-background ratio and limit their clinical application as diagnostic agents.
HGF, the only known ligand for c-Met, is usually secreted as an inactive polypeptide and cleaved by serine proteases into the bioactive format composed of a 69-kDa alpha chain and 34-kDa beta-chain, linked by a disulfide bond (9) . There have been several earlier attempts to express biologically active recombinant human HGF (rh-HGF) in both Escherichia coli and insect cells (13, 14) . Although biological activity of rh-HGF produced from E.coli has been reported to be equivalent to its native form (15) , the absence of the disulfide bond formation and lack of molecular glycosylation can potentially compromise its applicability in vivo.
Furthermore, production of rh-HGF in E.coli inclusion bodies involves a refolding process (15) , which is time-consuming and usually causes low protein production yield. Due to the similar reasons, insect cells are not ideal hosts for expressing human glycoproteins due to different glycosylation levels (16) . To attain rh-HGF with an equivalent structure to their native form, expression in mammalian cells including COS-1, rat hepatocytes and Chinese hamster ovary (CHO) cells is preferred (17) (18) (19) .
In this study, we use mammalian HEK293 cells to express 10His tagged rh-HGF. After attaining rh-HGF with high purity, we used PET imaging to investigate the in vivo distribution 
MATERIALS AND METHODS

Plasmids and Cell lines
The plasmid pCMV-hHGF-10his (Sino Biological Inc., Beijing, China) was used in the cloning and expression procedure. Large-scale plasmid DNA was extracted with an EZNA Plasmid Mini Kit II (Omega, Goraville, GA). The E.coli DH5α (Invitrogen, Carlsbad, CA) was used as a host for cloning of pCMV-hHGF-10his.
U87MG human glioblastoma and MDA-MB-231 human breast cancer lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured according to the supplier's instructions. All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. U87MG and MDA-MB-231 tumor models were prepared using a similar method as previously described (20) . The rh-HGF encoded by pCMV carries 10 histidine residues at its C-terminus. The Ni-NTA was balanced by binding buffer before the supernatant of cell lysis containing rh-HGF was added to the column, and the proteins associated with the resin were eluted by increasing concentrations of imidazole in the buffer. The details of purification procedures were performed using a method previously described (21) . The purity of rh-HGF was evaluated with 8% SDS-PAGE gel under non-reducing conditions stained with Coomassie brilliant blue R-250.
rh-HGF conjugation and Radiolabeling
NOTA-rh-HGF was prepared using a similar method as previously described (20) . Briefly, NOTA conjugation was carried out at pH 9.0 with the reaction ratio of p-SCN-Bn-NOTA:rh-HGF being 10:1at room temperature for 1 h. PD-10 columns were used to purify NOTA-rh-HGF with PBS as the mobile phase. Similar reaction conditions were adopted for the conjugation of rh-HGF with NHS-Fluorescein (Thermo Scientific, Pierce, USA).
64
Cu labeling and purification followed the routine protocol described by our group previously (20) . 64 CuCl 2 (37 MBq) was diluted in 300 μL of 0.1M sodium acetate buffer (pH 6.5) and added to 20 μg of NOTA-rh-HGF.
Flow cytometry
The biological activity of purified rh-HGF was evaluated by flow cytometry. Briefly, U87MG
and MDA-MB-231 cells were incubated with 20 μg/mL rh-HGF for 1 h. Subsequently, the cells Cu-NOTA-dnrh-HGF. Biodistribution studies were performed after the last PET scans at 24 h p.i. to validate the PET data. The tumors, liver and muscle were also frozen and cryosectioned for histologic analysis. Quantitative data were expressed as mean ± SD. Means were compared using the Student t test. P values of less than 0.05 were considered statistically significant.
Histology
After blocking with 10% donkey serum, frozen tissue slices of 5 μm thickness were incubated with rh-HGF (20 μg/mL) for 1 h at 4 ˚C. After washing with PBS, the slices were incubated with mouse anti-human HGF MAb for 4 h, followed by FITC-labeled goat anti-mouse IgG for 1 h.
The tissue slices were also stained with rat anti-human c-Met antibody and Cy3-labeled donkey by on October 29, 2017. For personal use only. jnm.snmjournals.org Downloaded from anti-rat IgG. All images were acquired with a Nikon Ti Eclipse confocal microscope (Nikon, Tokyo, Japan).
RESULTS
Expression and purification of rh-HGF
To attain high level of rh-HGF, the human cytomegalovirus (CMV) promoter was chosen due to its potent expression efficiency for downstream gene. As shown in Figure 1A , under CMV driven constitutive promoter, human HGF gene can be expressed in mammalian cells as a tagged protein with a C-terminal 10His tag, which can be used for further product purification. Transient transfections were performed using a mammalian cell line HEK293 using the procedures described above. After 2 days of incubation with Fugene HD and recombinant plasmid, protein production yield was initially tested by SDS-PAGE. After the confirmation of high-yield protein production in the cells, large-scale purification was carried out. After cell lysis, Ni-NTA resin was used to capture the 10His tagged rh-HGF. The schematic workflow for rh-HGF protein expression and purification is illustrated in Figure 1B . There was one clear band at 90 kDa on SDS-PAGE under non-reducing conditions, which represented the bioactive rh-HGF, and its purity was 85% ~ 90%. Two weak bands at the molecular weight of 60 and 34 kDa were also shown on SDS-PAGE, corresponding to α chain and β chain of HGF respectively ( Figure 1C) . Figure 2C showed that there were no observable differences in cellular uptake between FITC-rh-HGF and FITC-NOTA-rh-HGF, while the uptake of FITC-rh-HGF was significantly higher than that of FITC-dnrh-HGF. Combined with the fact that uptake of FITC-rh-HGF was extremely low in MDA-MB-231, these results confirmed that NOTA conjugation did not compromise the binding affinity or specificity of rh-HGF for c-Met.
Characterization of rh-HGF
PET and Biodistribution Studies
Time points of 0.5, 3, 9, 15 and 24 h p.i. were chosen for serial PET scans after intravenous injection of 64 Cu-NOTA-rh-HGF into tumor-bearing mice. The coronal slices that contained the tumors are shown in Figure 3 and the quantitative data obtained from region-of-interest analysis of PET results are shown in Figure 4 . In the U87MG tumor, which expresses high level of c-Met, 64 Cu-NOTA-rh-HGF had a rapid accumulation and tumor uptake was clearly visible at 0.5 h p.i., peaked at 9 h p.i., and remained stable over time (5.5 ± 2.0, 6.7 ± 1.5, 6.8 ± 1.8, 5.9 ± 1.4 and 5.4 ± 0.9 %ID/g at 0.5, 3, 9, 15 and 24 h p.i. respectively; n = 4; Figure 4A ). The liver uptake (36.0 ± 0.3, 32.7 ± 4.5, 26.0 ± 3.0, 24.5 ± 4.3 and 21.3 ± 2.7 %ID/g at 0.5, 3, 9, 15 and 24 h p.i., respectively) and kidney radioactivity (30.5 ± 1.0, 26.6 ± 1.3, 19.6 ± 1.0, 14.3 ± 1.1 and 10.0 ± 2.2 %ID/g at 0.5, 3, 9, 15 and 24 h p.i., respectively; Figure 4A ) was similar to those in c-Met negative MDA-MB-231 tumor models. The uptake in most other organs was at a very low level. Cu-NOTA-rh-HGF in MDA-MB-231 tumor was low (1.5 ± 2.0, 1.6 ± 0.5, 1.8 ± 0.6, 1.7 ± 0.6 and 1.6 ± 0.6 %ID/g at 0.5, 3, 9, 15 and 24 h after injection, respectively; n = 3; Figure 4B ). These values were significantly lower than those of U87MG tumors at all-time points (P < 0.05), indicating that c-Met targeting is the primary factor for the prominent uptake of 64 Cu-NOTA-rh-HGF in the U87MG tumor. 64 Cu-NOTA-dnrh-HGF (which was heat denatured hence does not bind to c-Met) had significantly lower U87MG tumor uptake than 
DISCUSSION
The HGF/c-Met signaling pathway has emerged as a promising therapeutic target for inhibiting tumor growth (22) . Activation or upregulation of c-Met is a negative prognostic indicator for various carcinomas, multiple myeloma, or glioma (9) . Several strategies to inhibit c-Met activation are currently under clinical evaluation, such as the use of tyrosine kinase inhibitors, monoclonal antibodies (against the receptor or ligand), and compounds against cMet/HGF (8, 23) . To obtain more accurate clinic outcome, suitable biomarkers for non-invasive monitoring and predicting response to those therapies are needed. To avoid proteolytic digestion and complexity in downstream processes including disulfide bonds and unique glycosylation patterns, the production of HGF requires eukaryotic or even mammalian expression systems to achieve high yields of functional active protein (29) . A simple but robust protocol was established in this study using pCMV standard vector with 10His tag and SDS-PAGE gel analysis showed a major constituent with a molecular weight of 90 kDa, standing for purified rh-HGF. Two weak bands about 60 and 30-kDa were also seen on SDS-PAGE, which was consist with the reported result of rh-HGF in CHO expression system since there is an equilibrium between rh-HGF and its α/β chain (19) . 10His Tag was used to simplify the production and characterization of rh-HGF, which did not affect the function of rh-HGF, confirmed by potent and specific binding capacity of rh-HGF to c-Met based on flow cytometry (Figure 2 ). The 10His tag can also be a potential binding site for 99m Tc (30) , which can be used for future SPECT imaging.
To the best of our knowledge, imaging of c-Met with rh-HGF has not been reported to date.
In this study, we have successfully developed and characterized 
